Paratek Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Paratek Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Paratek Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Paratek Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Paratek Pharmaceuticals Inc (Paratek) is a biopharmaceutical company that develops and commercializes therapies based on tetracycline chemistry. The company focuses on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Nuzyra (Omadacycline), the company’s lead product candidate, is a USFDA-approved broad-spectrum antibiotic for the treatment of adults with community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. XHANCE is a prescription nasal spray approved by the U.S. FDA for the treatment of chronic rhinosinusitis with or without nasal polyps in adults. Its other product, Seysara (sarecycline), is also a USFDA-approved drug for the treatment of inflammatory acne vulgaris in patients. Paratek is headquartered in Boston, Massachusetts, the US.
Headquarters
United States of America
Address
Suite 500, 75 Arlington Street, Boston, Massachusetts, 02116
Website
www.paratekpharma.com
Telephone
1 617 8076600
No of Employees
269
Industry
Pharmaceuticals and Healthcare
Revenue (2022)
$160.3M
Paratek Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Omadacycline: For treatment of adults with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infection (ABSSSI) caused by select susceptible microorganisms. | Nuzyra |
| XHANCE (fluticasone propionate) Nasal Spray | Seysara |
| Sarecycline: For treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. | XHANCE |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In March, the company merged with Radius Health Inc. |
| 2025 | Acquisitions/Mergers/Takeovers | In May, the company completed the acquisition of Optinose for US$330 million. |
| 2023 | Acquisitions/Mergers/Takeovers | In September, the company got acquired by Gurnet Point Capital and Novo Holdings A/S. |
Competitor Comparison
| Key Parameters | Paratek Pharmaceuticals Inc | Merck & Co Inc | Pfizer Inc | AbbVie Inc | Abbott Laboratories |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Boston | Rahway | New York City | North Chicago | Abbott Park |
| State/Province | Massachusetts | New Jersey | New York | Illinois | Illinois |
| No. of Employees | 269 | 75,000 | 75,000 | 57,000 | 115,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Evan Loh, MD | Chief Executive Officer; Director | Executive Board | 2019 | - |
| Karen Mcgrath | Chief People Officer | Senior Management | - | - |
| Jonathan Light | Chief Compliance Officer; Secretary; General Counsel | Senior Management | 2024 | - |
| Adam Woodrow | President; Chief Commercial Officer | Senior Management | 2019 | - |
| Randy Brenner | Chief Development and Regulatory Officer | Senior Management | 2019 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer